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Human respiratory syncytial virus (HRSV) is the leading cause of bronchiolitis and   
pneumonia in infants, children, the elderly and the immune-compromised. The goal of 
immunization is to provide sufficient protection to prevent serious lower respiratory tract 
diseases leading to hospitalization and reducing the frequency of complications such as 
otitis media. Prevention and treatment of HRSV infection using antiviral agents is 
challenging because it is a rapid acute infection and by the time the infection is 
recognized it may be too late to control the disease with any antiviral therapy alone. 
Thus, there is a worldwide need for an HRSV vaccine.  
 
Studies have shown that the immunogenic domains of F and G proteins could confer 
protection against HRSV infection in vaccinated hosts. In the present study, firstly the 
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immunogenic domain of HRSV G domain was expressed in Escherichia coli . Then a 
rabbit was immunized using purified-recombinant G domain protein. The results of 
neutralization assay showed that G domain alone could raise active polyclonal 
antibodies against HRSV successfully. Secondly, the potential of G and F immunogenic 
domains as vaccine candidates were studied by using live bacterial vaccines. Both the G 
and F domains were separately initially cloned in pKMSInak plasmid before they were 
surface displayed on Salmonella typhi Ty21a used as the delivery system. The surface 
displayed G and F domains were detected using indirect immunofluorescence, sero-
agglutination and outer membrane protein separation approaches suggesting that the 
Inak protein successfully carried the G and F domains to the surface of Salmonella cells.  
For in vivo evaluation of the designed vaccines, Balb/c mice were immunized orally 
with live Salmonella cells harboring pKMSInak-G or pKMSInak-F and challenged 
against HRSV.  
 
The humoral (TH2), cellular (TH1) and mucosal immune (IgA) responses of the 
immunized mice were studied by measuring cytokines (IL-2, IL-4, IL-5, IL-9, IL-10, IL-
12, IL-13, IL-17, IFN-γ and TNF-α), chemokines (RANTES and MIP-α) and 
immunoglobulins (IgG, IgG1, IgG2a, IgG2b and IgA) levels in their sera before and 
after challenging with HRSV. Lymphocyte proliferation assay was performed to  
evaluate the cell mediated immunity. Histopathological examinations were also carried 
out as confirmatory tests. The results showed that pKMSInak-G and pKMSInak-F 
vaccines could significantly enhance TH1 and TH2 responses as well as mucosal 
immunity in the immunized mice compared to the control group. Histopathological 
examinations indicated that the immunized mice had significantly lesser lung tissue 
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damage than the control. Moreover, the obtained ratios of TH1/TH2 were desirable (~1) 
suggesting that Salmonella cells carrying pKMSInak-G and pKMSInak-F are potent 
vaccine candidates against HRSV. 
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Virus sinsitium pernafasan manusia (hRSV) merupakan penyebab utama kepada 
jangkitan bronchiolitis dan pneumonia di kalangan bayi, kanak-kanak, dewasa dan 
pesakit kurang daya tahan. Memandangkan jangkitan RSV tidak dapat dibendung 
sekaligus, matlamat pengimunan adalah untuk memberikan perlindungan secukupnya 
untuk menghalang penyakit bahagian bawah sistem pernafasan yang serius sehingga 
mengakibatkan kemasukkan ke hospital dan mengurangkan frekuensi komplikasi seperti 
otitis media.  Pencegahan dan rawatan bagi jangkitan RSV menggunakan agen antivirus 
memberikan cabaran kerana ia merupakan satu jangkitan akut yang pesat dan mungkin 
terlambat untuk mengawal penyakit itu dengan mana-mana terapi antivirus apabila 
jangkitan dikesan.  Oleh yang demikian, vaksin terhadap RSV adalah diperlukan di 
seluruh dunia. 
Kajian telah menunjukkan bahawa domain imunogenik protein F dan G boleh 
memberikan perlindungan terhadap jangkitan RSV dalam hos yang divaksinkan. Untuk 
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menilai keimunogenan gen yang terpilih, pertamanya domain G diekspreskan di dalam 
sistem pengekspresan bakteria (E. coli). Kemudian, arnab disuntik dengan domain G 
yang telah ditulenkan.  Keputusan daripada penetapan kadar peneutralan menunjukkan 
bahawa domain G sahaja berjaya mengaruhkan antibodi poli-klon. Keduanya, potensi 
domain imunogenik G dan F sebagai calon vaksin telah dikaji dengan menggunakan 
vaksin bakteria hidup. Kedua-dua domain G dan F pada mulanya diklonkan secara 
berasingan ke  dalam plasmid pKMSInak sebelum ianya wujud pada bahagian 
permukaan Salmonella typhimurium 21a. Permukaan di sel yang mempamerkan domain 
G dan F telah dikesan dengan menggunakan imunopendarfluor secara tak langsung, 
sero- pengaglutinatan dan pendekatan pemisahan protein membran luar yang mana 
mencadangkan protein Inak dengan jayanya dapat membawa domain-domain ke 
permukaan Salmonella.  Penilaian secara in vivo untuk penghasilan vaksin, tikus Balb/c 
telah disuntik secara oral dengan sel hidup Salmonella yang mempunyai pKMSInak-G 
or pKMSInak-F dan  menentang RSV. 
 
Respon bagi keimunan humoral (TH2), selular (TH1) dan mukosa (IgA) yang  telah 
disuntik pada tikus dikaji dengan menganalisa sitokin (IL-2, IL-4, IL-5, IL-9, IL-10, IL-
12, IL-13, IL-17, IFN-γ and TNF-α), chemokines (RANTES AND MIP-α) dan 
imunoglobulin (IgG, IgG1, IgG2a, IgG2b and IgA) secara berperingkat serta ujian 
percambahan limfosit. Ujian histopatologi turut dijalankan sebagai ujian-ujian 
pengesahan. Keputusan menunjukkan bahawa vaksin pKMSInak-G dan pKMSInak-F itu 
boleh meningkatkan respon-respon TH1 dan TH2 serta keimunan mukosa tikus yang 
disuntik berbanding dengan kumpulan kawalan. Ujian histopatologi juga menunjukkan 
bahawa tikus-tikus yang telah diimunisasi mempunyai kerosakan tisu paru-paru yang 
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sedikit berbanding dengan kawalan. Tambahan pula, nisbah TH1/TH2 yang telah 
diperolehi (~ 1) menunjukkan sel-sel Salmonella yang membawa pKMSInak-G and 
pKMSInak-F merupakan vaksin yang berpotensi menentang jangkitan HRSV. 
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